Endocyte
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
You can watch Endocyte and buy or sell other stocks, options, and ETFs commission-free!About ECYT
Endocyte, Inc., a biopharmaceutical company, develops receptor-targeted therapeutics to treat cancer and autoimmune/inflammatory diseases. The company provides EC17, a folate-targeted hapten therapy drug to treat metastatic renal and ovarian cancer; EC145, a folate-targeted chemotherapeutic conjugate to treat various tumors, including cancers of the breast, lung, and blood; EC0225, a targeted chemotherapy drug; BMS753493, a folate-targeted anti-cancer therapy drug; EC0434 to target folate receptor positive tumors; and EC0305, an anti-cancer therapy drug.
CEOMichael A. Sherman, MBA
CEOMichael A. Sherman, MBA
Employees—
Employees—
HeadquartersWest Lafayette, Indiana
HeadquartersWest Lafayette, Indiana
Founded1995
Founded1995
Employees—
Employees—
ECYT Key Statistics
Market cap1.95B
Market cap1.95B
Price-Earnings ratio-35.02
Price-Earnings ratio-35.02
Dividend yield—
Dividend yield—
Average volume1.68M
Average volume1.68M
High today—
High today—
Low today—
Low today—
Open price—
Open price—
Volume0.00
Volume0.00
52 Week high$24.00
52 Week high$24.00
52 Week low$2.81
52 Week low$2.81